Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SMNP (National Institute of Allergy and Infectious Diseases)
- Development stage
- Unknown
- Lead developer
- National Institute of Allergy and Infectious Diseases
- Modality
- Nanoparticles → Drug Delivery Systems
- Administration
- Intramuscular, Subcutaneous
01
Overview
**SMNP** is an investigational nanoparticle vaccine adjuvant composed of a saponin component, monophosphoryl lipid A, cholesterol, and phospholipid; clinical-grade material has been reported to use QS-21 saponin and dipalmitoylphosphatidylcholine. MPLA provides Toll-like receptor 4 stimulation, while the saponin-containing nanoparticle promotes antigen transport to draining lymph nodes and supports innate activation, germinal-center responses, T-cell help, and durable antibody and memory-B-cell responses. SMNP contains no HIV antigen itself; it is being evaluated as the adjuvant administered with the germline-targeting HIV envelope trimer N332-GT5 gp140 in the Phase 1 HVTN 144 study in adults without HIV. ([jci.org](https://www.jci.org/articles/view/185292))
- Other names
- Saponin/MPLA nanoparticlesSaponin-MPLA nanoparticlesSaponin monophosphoryl lipid A nanoparticlesQS-21-MPLA nanoparticleQS21-MPLA nanoparticleQS 21-MPLA nanoparticle
02
Targets
TLR4 (Toll-like receptor 4)
Beyond the preview
Go deeper on SMNP (National Institute of Allergy and Infectious Diseases).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SMNP (National Institute of Allergy and Infectious Diseases).